Alexandra Thomas

20PUBLICATIONS
78CO-AUTHORS
Molecular targetsHealth informatics and information systemsMedical devicesOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 14, 2026
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Kathy D Miller, Alexandra Thomas, Sandra Althouse

|Oct 09, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.

Alexandra Thomas, Erica L Mayer, Angela DeMichele

|Sep 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Rebecca A Shatsky, Meghna S Trivedi, Christina Yau

|Sep 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Katia Khoury, Jane L Meisel, Christina Yau

|Jun 23, 2023
Rare subtypes of triple negative breast cancer: Current understanding and future directions.

Alexandra Thomas, Jorge S Reis-Filho, Charles E Geyer

|Dec 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience.

Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein

Pageof 4

Frequent Collaborators

3 joint publications

Angela DeMichele

3 joint publications

Kevin M Kalinsky

3 joint publications

Jennifer H Jordan

2 joint publications

Caroline E Miller